Skip to main content
Top
Published in: Tumor Biology 2/2013

01-04-2013 | Research Article

Prognostic value of tumor size in gastric cancer: an analysis of 2,379 patients

Authors: Pengtao Guo, Yangming Li, Zhi Zhu, Zhe Sun, Chong Lu, Zhenning Wang, Huimian Xu

Published in: Tumor Biology | Issue 2/2013

Login to get access

Abstract

Tumor size has been included into the staging systems of many solid tumors, such as lung and breast. However, tumor size is not integrated in the staging of gastric cancer, and its prognostic value for gastric cancer needs to be reappraised. A total of 2,379 patients who received radical resection for histopathologically confirmed gastric adenocarcinoma were enrolled in the present study. Tumor size, originally presented as continuous variable, was categorized into small gastric cancer (SGC) group and large gastric cancer (LGC) group using an optimal cutoff point determined by Cox proportional hazards model. The associations between tumor size and other clinicopathological factors were checked using Chi-square test. Survival of gastric cancer patients was estimated by using univariate Kaplan–Meier method, and the survival difference was checked by using the log-rank test. The significant clinicopathological factors were included into the Cox proportional hazards model to determine the independent prognostic factors, and their hazard ratios were calculated. With the optimal cutoff point of 4 cm, tumor size was categorized into SGC group (≤4 cm) and LGC group (>4 cm). Tumor size closely correlated with age, tumor location, macroscopic type, Lauren classification, and lymphatic vessel invasion. Moreover, tumor size was also significantly associated with depth of tumor invasion and status of regional lymph nodes. The 5-year survival rate was 68.7 % for SGC group which was much higher than 40.2 % for LGC group. Univariate analysis showed that SGC had a better survival than LGC, mainly for patients with IIA, IIB, and IIIA stage. Multivariate analysis revealed that tumor size as well as age, tumor location, macroscopic type, Lauren classification, lymphatic vessel invasion, depth of tumor invasion, and status of regional lymph nodes were independent prognostic factors for gastric cancer. Tumor size is a reliable prognostic factor for patients with gastric cancer, and the measurement of tumor size would be helpful to the staging and management of gastric cancer.
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC CancerBase no. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 1/6/2012. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC CancerBase no. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://​globocan.​iarc.​fr, accessed on 1/6/2012.
2.
go back to reference Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12(1):17–20.PubMed Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12(1):17–20.PubMed
3.
go back to reference Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer. 1998;1(2):125–33.PubMedCrossRef Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer. 1998;1(2):125–33.PubMedCrossRef
4.
go back to reference Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–61.PubMedCrossRef Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–61.PubMedCrossRef
5.
go back to reference Mohri Y, Tanaka K, Ohi M, Yokoe T, Miki C, Kusunoki M. Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg. 2010;34(2):285–90.PubMedCrossRef Mohri Y, Tanaka K, Ohi M, Yokoe T, Miki C, Kusunoki M. Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg. 2010;34(2):285–90.PubMedCrossRef
6.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12.CrossRef
7.
go back to reference Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. American Joint Committee on Cancer, American Cancer Society: AJCC cancer staging manual. 7th ed. New York: Springer; 2010. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. American Joint Committee on Cancer, American Cancer Society: AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
8.
go back to reference Wang X, Wan F, Pan J, Yu GZ, Chen Y, Wang JJ. Tumor size: a non-neglectable independent prognostic factor for gastric cancer. J Surg Oncol. 2008;97(3):236–40.PubMedCrossRef Wang X, Wan F, Pan J, Yu GZ, Chen Y, Wang JJ. Tumor size: a non-neglectable independent prognostic factor for gastric cancer. J Surg Oncol. 2008;97(3):236–40.PubMedCrossRef
9.
go back to reference Giuliani A, Caporale A, Di Bari M, Demoro M, Gozzo P, Corona M, Miccini M, Ricciardulli T, Tocchi A. Maximum gastric cancer diameter as a prognostic indicator: univariate and multivariate analysis. J Exp Clin Cancer Res. 2003;22(4):531–8.PubMed Giuliani A, Caporale A, Di Bari M, Demoro M, Gozzo P, Corona M, Miccini M, Ricciardulli T, Tocchi A. Maximum gastric cancer diameter as a prognostic indicator: univariate and multivariate analysis. J Exp Clin Cancer Res. 2003;22(4):531–8.PubMed
10.
go back to reference Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Oro S, Tatebe S, Tsujitani S, Ikeguchi M. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg. 2006;192(3):296–300.PubMedCrossRef Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Oro S, Tatebe S, Tsujitani S, Ikeguchi M. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg. 2006;192(3):296–300.PubMedCrossRef
11.
go back to reference Adachi Y, Oshiro T, Mori M, Maehara Y, Sugimachi K. Tumor size as a simple prognostic indicator for gastric carcinoma. Ann Surg Oncol. 1997;4(2):137–40.PubMedCrossRef Adachi Y, Oshiro T, Mori M, Maehara Y, Sugimachi K. Tumor size as a simple prognostic indicator for gastric carcinoma. Ann Surg Oncol. 1997;4(2):137–40.PubMedCrossRef
12.
go back to reference Xu CY, Shen JG, Shen JY, Chen WJ, Wang LB. Ulcer size as a novel indicator marker is correlated with prognosis of ulcerative gastric cancer. Dig Surg. 2009;26(4):312–6.PubMedCrossRef Xu CY, Shen JG, Shen JY, Chen WJ, Wang LB. Ulcer size as a novel indicator marker is correlated with prognosis of ulcerative gastric cancer. Dig Surg. 2009;26(4):312–6.PubMedCrossRef
13.
go back to reference Yokota T, Ishiyama S, Saito T, Teshima S, Yamada Y, Iwamoto K, Takahashi M, Murata K, Yamauchi H. Is tumor size a prognostic indicator for gastric carcinoma? Anticancer Res. 2002;22(6B):3673–7.PubMed Yokota T, Ishiyama S, Saito T, Teshima S, Yamada Y, Iwamoto K, Takahashi M, Murata K, Yamauchi H. Is tumor size a prognostic indicator for gastric carcinoma? Anticancer Res. 2002;22(6B):3673–7.PubMed
14.
go back to reference Kunisaki C, Makino H, Takagawa R, Oshima T, Nagano Y, Kosaka T, Ono HA, Otsuka Y, Akiyama H, Ichikawa Y, Shimada H. Tumor diameter as a prognostic factor in patients with gastric cancer. Ann Surg Oncol. 2008;15(7):1959–67.PubMedCrossRef Kunisaki C, Makino H, Takagawa R, Oshima T, Nagano Y, Kosaka T, Ono HA, Otsuka Y, Akiyama H, Ichikawa Y, Shimada H. Tumor diameter as a prognostic factor in patients with gastric cancer. Ann Surg Oncol. 2008;15(7):1959–67.PubMedCrossRef
15.
go back to reference Jun KH, Jung H, Baek JM, Chin HM, Park WB. Does tumor size have an impact on gastric cancer? A single institute experience. Langenbecks Arch Surg. 2009;394(4):631–5.PubMedCrossRef Jun KH, Jung H, Baek JM, Chin HM, Park WB. Does tumor size have an impact on gastric cancer? A single institute experience. Langenbecks Arch Surg. 2009;394(4):631–5.PubMedCrossRef
16.
go back to reference Otsuji E, Kuriu Y, Ichikawa D, Ochiai T, Okamoto K, Yamagishi H. Prediction of lymph node metastasis by size of early gastric carcinoma. Hepatogastroenterology. 2007;54(74):602–5.PubMed Otsuji E, Kuriu Y, Ichikawa D, Ochiai T, Okamoto K, Yamagishi H. Prediction of lymph node metastasis by size of early gastric carcinoma. Hepatogastroenterology. 2007;54(74):602–5.PubMed
17.
go back to reference Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H, Tsuburaya A. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1. Gastric Cancer. 2011;14(3):274–8.PubMedCrossRef Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H, Tsuburaya A. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1. Gastric Cancer. 2011;14(3):274–8.PubMedCrossRef
18.
go back to reference Liu X, Xu Y, Long Z, Zhu H, Wang Y. Prognostic significance of tumor size in T3 gastric cancer. Ann Surg Oncol. 2009;16(7):1875–82.PubMedCrossRef Liu X, Xu Y, Long Z, Zhu H, Wang Y. Prognostic significance of tumor size in T3 gastric cancer. Ann Surg Oncol. 2009;16(7):1875–82.PubMedCrossRef
19.
go back to reference Bilici A, Uygun K, Seker M, Ustaalioglu BB, Aliustaoglu M, Temiz S, Aksu G, Gezen C, Yavuzer D, Kaya S, Salepci T, Mayadagli A, Gumus M. The effect of tumor size on overall survival in patients with pT3 gastric cancer: experiences from 3 centers. Onkologie. 2010;33(12):676–82.PubMedCrossRef Bilici A, Uygun K, Seker M, Ustaalioglu BB, Aliustaoglu M, Temiz S, Aksu G, Gezen C, Yavuzer D, Kaya S, Salepci T, Mayadagli A, Gumus M. The effect of tumor size on overall survival in patients with pT3 gastric cancer: experiences from 3 centers. Onkologie. 2010;33(12):676–82.PubMedCrossRef
20.
go back to reference Yokota T, Kunii Y, Saito T, Teshima S, Yamada Y, Iwamoto K, Takahashi H, Takahashi M, Kikuchi S, Yamauchi H. Prognostic factors of gastric cancer tumours of less than 2 cm in diameter: rationale for limited surgery. Eur J Surg Oncol. 2002;28(3):209–13.PubMedCrossRef Yokota T, Kunii Y, Saito T, Teshima S, Yamada Y, Iwamoto K, Takahashi H, Takahashi M, Kikuchi S, Yamauchi H. Prognostic factors of gastric cancer tumours of less than 2 cm in diameter: rationale for limited surgery. Eur J Surg Oncol. 2002;28(3):209–13.PubMedCrossRef
21.
go back to reference Li C, Oh SJ, Kim S, Hyung WJ, Yan M, Zhu ZG, Noh SH. Risk factors of survival and surgical treatment for advanced gastric cancer with large tumor size. J Gastrointest Surg. 2009;13(5):881–5.PubMedCrossRef Li C, Oh SJ, Kim S, Hyung WJ, Yan M, Zhu ZG, Noh SH. Risk factors of survival and surgical treatment for advanced gastric cancer with large tumor size. J Gastrointest Surg. 2009;13(5):881–5.PubMedCrossRef
Metadata
Title
Prognostic value of tumor size in gastric cancer: an analysis of 2,379 patients
Authors
Pengtao Guo
Yangming Li
Zhi Zhu
Zhe Sun
Chong Lu
Zhenning Wang
Huimian Xu
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0642-6

Other articles of this Issue 2/2013

Tumor Biology 2/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine